Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease. Issue 1 (25th July 2018)

• Record Type: Journal Article
• Authors: Belitskaya‐Lévy, Ilana; Dysken, Maurice; Guarino, Peter; Sano, Mary; Asthana, Sanjay; Vertrees, Julia E.; Pallaki, Muralidhar; Llorente, Maria; Love, Susan; Schellenberg, Gerard
• Is Part Of: Alzheimer's & dementia. Volume 4:Issue 1(2018)
• Page Start: 344
• Page End: 349
• Publication Date: 2018-07-25
• Subjects: Alzheimer's disease -- Vitamin E -- Memantine -- Apolipoprotein E genotypes -- ApoE genotypes -- APOE ε4 allele -- Genotype‐treatment interaction; Dementia -- Periodicals; Dementia -- Treatment -- Periodicals; Alzheimer's disease -- Treatment -- Periodicals; Alzheimer's disease -- Periodicals; 616.831
• DOI: 10.1016/j.trci.2018.06.001
• Languages: English
• ISSNs: 2352-8737

Abstract

Abstract: Introduction: Because apolipoprotein E (APOE) genotypes are known risk factors for Alzheimer's disease (AD), they have been measured in clinical trial participants to determine their effect on treatment outcome. Methods: We determined APOE genotypes in a subset of subjects (N = 415) who participated in a randomized controlled trial of vitamin E and memantine in 613 veterans with mild‐to‐moderate AD. Results: Similar to the primary study, substudy participants receiving vitamin E also had slower functional decline than those receiving placebo. Overall, there was no difference in the rate of functional decline between APOE ε4 allele carriers and noncarriers. A significant interaction was observed between treatment and the APOE genotype on AD progression: ε4 carriers declined faster than noncarriers in the vitamin E plus memantine treatment arm. Discussion: APOE genotypes may modulate AD treatment response and should be included in the design of future randomized controlled trials.